Articles

Follicum Doses First Patients In Topical Phase 2 Trial

March 11, 2020 /

Phase 2 Trial Of Topical FOL-005 Has Resumed- Update 6/9/20 After a nearly 3 month intermission due to coronavirus restraints, Follicum is now able to continue recruitment for its phase 2 trial of a topical FOL-005 formulation. In addition to restarting the trial, Follicum has enlisted a third study center, CentroDerm of Wuppertal, Germany, to…

Shiseido Releases RCH-01 Trial Results 2020

March 7, 2020 /

Replicel Terminates License With Shiseido: Update (12/21/21) Two months after Replicel announced that it was entering arbitration proceedings with Shiseido, the company has announced today that it has terminated its license agreement with Shiseido. The license agreement between Replicel and Shiseido dates back to 2013 when Shiseido paid an upfront fee to gain the rights…

Histogen Merges With Conatus Pharmaceuticals

January 30, 2020 /

Histogen is finally becoming a publicly traded company in 2020 after latest merger deal. On January 28, 2020, Histogen and Conatus Pharmaceuticals issued a press release announcing a definitive merger agreement between the two companies. Like Histogen, Conatus Pharmaceuticals is a biotech company based in San Diego, CA. Conatus has been publicly traded on Nasdaq…

RiverTown Featured In Latest Gray Hair Cure Research

January 28, 2020 /

RT160 Gray Hair Reversal Published Study (7/13/20) Last week, a new peer-reviewed article on RiverTown Therapeutics’ RT1640 was published in the Pigment Cell & Melanoma Research journal. The study is titled “Topical RT1640 treatment effectively reverses gray hair and stem cell loss in a mouse model of radiation‐induced canities” and was led by Dr. Melissa…

Follica Presents Topline Data From FOL-004 Treatment

December 19, 2019 /

Updated 12/19/19 Today, I received an email from Follica management which shared the company’s latest press release. The company has just announced positive topline data from its FOL-004 safety and efficacy optimization study which was carried out in 2019. According to the release, the study was designed to determine the optimal treatment regimen involving Follica’s…

Allergan Invests $25 Million Into New Hair Loss Drugs

November 14, 2019 /

The medical aesthetic giant Allergan is doubling down on its mission to cure baldness. Collaboration With Exicure Did it seem like research and development was slowing down in the hair growth treatment sector? Allergan doesn’t think so. Today, November 14, 2019, it was announced that Allergan has invested $25 million in the company Exicure to…

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.